Aptevo Therapeutics Reports $12.6 Million Net Loss, Expands Product Pipeline

Aptevo Therapeutics Inc. reported a net loss of $12.6 million for the six months ended June 30, 2025, a slight decrease from the $12.7 million loss recorded during the same period in 2024. The company’s total revenue remains at zero, as it has not yet commercialized any products. Operating expenses for the first half of 2025 were $6.96 million, down from $7.40 million in the prior year, primarily due to reduced research and development costs. The company’s cash and cash equivalents increased to $9.41 million as of June 30, 2025, compared to $8.71 million at the end of 2024.

In terms of strategic developments, Aptevo has expanded its product pipeline with the introduction of APVO455, a bispecific antibody targeting Nectin-4 and CD3, aimed at treating multiple solid tumors. The company continues to advance its lead clinical candidate, mipletamig, which is currently in a Phase 1b/2 trial for acute myeloid leukemia (AML). The trial has reported an 85% remission rate among patients treated with mipletamig in combination with standard therapies. Additionally, Aptevo has secured financing totaling $15.9 million through various equity offerings, which is expected to extend its cash runway into late 2025.

Operationally, Aptevo has seen a significant increase in its common stock outstanding, rising to 3,224,156 shares as of June 30, 2025, following a reverse stock split executed in May 2025. The company has also entered into a Standby Equity Purchase Agreement with Yorkville, allowing it to raise up to $25 million over the next three years. This agreement, along with an At The Market Offering Agreement, provides Aptevo with additional avenues for capital generation, which is critical given its ongoing need for funding to support clinical trials and operational expenses.

Looking ahead, Aptevo acknowledges the challenges it faces, including the need for additional funding to support its clinical development programs and the potential for delays in obtaining regulatory approvals. The company has expressed concerns regarding its ability to continue as a going concern, emphasizing the necessity of raising further capital to sustain its operations. The management has indicated that it may need to make strategic adjustments, including potential reductions in research and development spending, if it cannot secure the necessary funding in a timely manner.